Serum soluble Fas-ligand levels and flow-mediated vasodilation in patients undergoing peritoneal dialysis

Abstract. Flow-mediated vasodilation (FMD) has been demonstrated to be a useful, non-invasive tool for the detection of endothelial dysfunction in atherosclerotic cardiovascular disease, leading cause mortality end-stage kidney disease. The Fas/Fas ligand system apoptosis resulting from activation caspase cascade- contributes pathophysiology atherosclerosis. This ‘apoptotic’ plays central role immune homeostasis. Vascular cells and inflammatory are main resources Fas ligand. In this study, we aimed investigate soluble (sFasL) as marker FMD peritoneal dialysis (PD) patients.
 Methods. A total 43 patients undergoing maintenance PD 40 healthy donors were enrolled cross-sectional observational study. Demographics, anthropometric measurements clinical examinations obtained. Endothelial function was evaluated by brachial artery with high-resolution ultrasonography. Serum sFasL concentrations measured an enzyme-linked immunosorbent assay kit. 
 Results. partisipants devited on 2 groups: who had treated at least 12 weeks (group 1; mean age 41±14 years, M/F: 22/21) gender matched controls 2; 50±12 19/20). forearm serum levels significantly lower (3.95±2.01 vs 8.83 ± 6.17; p<0.001 54 24 73 30; p=0.001). Forearm correlated (r=0.289; p=0.008), age, BMI uric acid (r= 0,32; p=0.003, respectively), hemoglobin 0,293; p=0.007), calcium 0,26; p=0.016), phosphate (r=- 0,250; p=0.023), magnesium 0,255; p=0.020), h SBP 0,257; p=0.019), creatinine iPTH 0.50 r=- 0,45; p<0.001, respectively). After adjustment stepwise multivariate analysis showed independently associated (β: 0.180; p=0.03, CI: 0.078-0.314). p=0.001).
 Conclusions. may used simple screening patients.